

Publications – (Listed in alphabetical order according to the first appearance of the ID faculty's name)

1. Yawson AE, Appaih LK, Yawson AO, Bonsu G, Aluze-Ele S, Amanhyia ON, Lartey M, Adjei AA, Lawson A, **Beckwith CG, Kwara AM, Flanigan T**. Sex differences in perceived risk and testing experience of HIV in an urban fishing setting in Ghana. *International Journal for Equity in Health* 2014; Nov 15;13(1):109. PMID: 25398271
2. Solomon L, Montague BT, **Beckwith CG**, Baillargeon J, Costa M, Dumont D, Kuo I, Kurth A, **Rich JD**. Survey finds that many prisons and jails have room to improve HIV testing and coordination of post release treatment. *Health Aff* 33(3):434-42, 2014. PMID: PMC4028701
3. Larney S, **Beckwith CG**, Zaller N, Montague B, **Rich JD**. Seek, test, treat and retain for hepatitis C in the United States criminal justice system. *Int J prisoner health* 10(3):164-71, 2014. PMID: PMC4358744
4. **Beckwith C**, Bazerman L, **Gillani F**, Tran L, Larson B, Rivard S, **Flanigan T, Rich JD**. The feasibility of implementing the HIV seek, test, and treat strategy in jails. *AIDS Pt Care STDs* 28(4): 183-7, 2014. PMID: PMC3985510
5. **Beckwith CG**, Kurth A, Bazerman L, Solomon L, Patry E, **Rich JD**, Kuo I. Survey of US Correctional Institutions for Routine HCV Testing. *American Journal of Public Health* 2015; Jan; 105 (1): 68-71. PMID: 25393180.
6. Peterson J, Cota M, Gray H, Bazerman L, Kuo I, Kurth A, **Beckwith CG**. Technology Use in Linking Criminal Justice Reentrants to HIV Care in the Community: A Qualitative Formative Research Study. *Journal of Health Communication* 2015; 20(3): 245-51. PMID: 25529057.
7. Lima VD, Graf I, **Beckwith CG**, Springer S, Altice F, Coombs D, Kim B, Messina L, Montaner J, Spaulding A. The Impact of Implementing a Test, Treat, and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model. *PLoS ONE* 2015; 10(4): e0123482. doi:10.1371/journal.pone.0123482.
8. Cribbs SK, Lennox J, **Caliendo AM**, Brown LA, Guidot DM. Healthy HIV-1-infected individuals of HAART harbor HIV-1 in their alveolar macrophages. *AIDS Research and Human Retroviruses*. 2015 Jan;31(1):64-70. doi: 10.1089/AID.2014.0133.
9. Abou Tayoun AN, Burchard PR, **Caliendo AM**, Scherer A, Tsongalis GJ. A multiplex PCR assay for the simultaneous detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis*. *Experimental and Molecular Pathology*. 2015 Apr;98(2):214-8. doi: 10.1016/j.yexmp.2015.01.011. Epub 2015 Jan 13.

10. Hayden RT, Gu Z, Sam SS, Sun Y, Tang L, Pounds S and **Caliendo AM**. Comparative Evaluation of three commercial quantitative cytomegalovirus standards using digital and real-time PCR. *J Clin Micro*. 2015 May;53(5):1500-5. doi: 10.1128/JCM.03375-14. Epub 2015 Feb 18.
11. **Chan PA**, Reitsma MB, DeLong A, Boucek B, Nunn A, Salemi M, **Kantor R**. (2014) "Phylogenetic and geospatial evaluation of HIV-1 subtype diversity at the largest HIV center in Rhode Island." *Infection, Genetics and Evolution*, Dec; 28: 258-66.
12. Nunn A, MacCarthy S, Barnett N, Rose J, **Chan P**, Yolken A, Cornwall A, Chamberlain N, Barnes A, Riggins R, Moore E, Simmons D, Parker S, Mena L. (2014) "Prevalence and Predictors of Concurrent Sexual Partnerships in a Predominantly African American Population in Jackson, Mississippi." *AIDS and Behavior*, Dec; 18(12):2457-68.
13. MacCarthy S, Men L, **Chan PA**, Rose J, Simmons D, Riggins R, Hoffman, Perez-Brumer A, Chamberlain, Nunn A. (2014) "Sexual network profiles and risk factors for STIs among African American sexual minorities in Mississippi: A cross-sectional analysis." *LGBT Health*, 2014.
14. **Chan PA**, Maher J, Poole D, Alexander-Scott N, Ducharme RB, Yates G, Benben S, Nunn A, Comella J, Bandy U, Montague BT, **Kojic E**, Chapin K, **Flanigan TP**. (2014) "Addressing the increasing burden of sexually transmitted infections in Rhode Island." *RI Med J*. Jan 5;98(1):31-4.
15. Rogo T, DeLong AK, **Chan PA**, **Kantor R**. (2015) "Antiretroviral Treatment Failure, Drug resistance and Subtype Diversity in the only Pediatric HIV Clinic in Rhode Island." *Clin. Infect Di*. May 1;60(9):1426-35.
16. Alexander J, Rose J, Dierker L, **Chan PA**, MacCarthy S, Simmons D, Mena L, Nunn A. (2015) "It is complicated: sexual partner characteristic profiles and sexually transmitted infection rates within a predominantly African American population in Mississippi." *Sex Transm Dis*. May;42(5):266-71.
17. Moitra E, **Chan PA**, Stein MD. (2015) "Open Trial of an Acceptance-Based Behavior Therapy Intervention to Engage Newly Diagnosed HIV Patients in Care: Rationale and Evidence of Feasibility and Acceptability." *Behav Modif*. 2015;39(5):670-90. PMID: 26111724
18. Trooskin SB, Poceta J, Towey CM, Yolken A, Rose JS, Luqman NL, Preston TW, **Chan PA**, **Beckwith C**, Feller SC, Lee H, Nunn AS. (2015) "Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program." *J Gen Intern Med*. 30:(7):950-7.
19. **Chan PA**, **Hogan JW**, Huang, A, DeLong A, Salemi M, Mayer KH, **Kantor R**. (2015) "Phylogenetic investigation of a statewide HIV-1 epidemic reveals ongoing and active transmission networks among men who have sex with men." *J Acquir Immune Defic Syndr*. 2015;70(4):428-35. PMID: 26258569

20. **Chan PA**, Rose J, Maher J, Benben S, Pfeiffer K, Almonte A, Poceta J, Oldenburg CE, Parker S, Marshall BD, **Lally M**, Mayer K, Mena L, Patel R, Nunn AS. (2015) "A latent class analysis of risk factors for acquiring HIV among men who have sex with men: Implications for implementing pre-exposure prophylaxis programs." *AIDS Patient Care and STDs*. 2015;29(11):597-605. PMID: 26389735
21. Glavis-Bloom J, Vasher S, Marmor M, Fine AB, **Chan PA**, **Tashima KT**, **Lonks JR**, **Kojic EM**. "Candida and cardiovascular implantable electronic devices: a case of lead and native aortic valve endocarditis and literature review." *Mycoses*. 2015;58(11):637-41. PMID: 26403965
22. Cunha BA, Lotholary O, **Cunha CB**: Fever of Unknown Origin (FUO). *Am. J Med* 128:1138.e1-1138.e15, 2015.
23. **Cu-Uvin S**, Workowski KA, Bolan GA; Centers for Disease Control and Prevention. *MMWR Recomm Rep*. Sexually transmitted diseases treatment guidelines. 2015;5:64(RR-03):1-137. PMID: 26042815
24. Mitchell SL, Shaffer ML, Loeb MB, Givens JL, Habtemariam D, Kiely DK, **D'Agata E**. Infections Management and Multidrug-resistant Organisms in Nursing Home Residents with Advanced Dementia. *JAMA Int Med* 2014;174;1660-7. PMID:25133863
25. **D'Agata EMC**, Habtemariam D, Mitchell SL. Multidrug-resistant gram-negative bacteria: intra- and inter- facility dissemination among residents with advanced dementia. *Infect Control Hosp Epidemiol* 2015;36;93-5. PMID:25920002
26. Givens JL, Spinellal S, Ankuda CK, **D'Agata E**, Shaffer ML, Habemariam D, Mitchell SL. Healthcare proxy awareness of suspected infections in nursing home residents with advanced dementia. *J Am Geriat Soc* 2015;63;1084-90. PMID:26031905
27. Monteiro JF, Galea S, **Flanigan TP**, Monteiro, ML, Friedman, SR, Marshall BDL. Evaluating HIV prevention strategies for populations in key affected groups: The example of Cabo Verde. (2015) *Int J Public Health*. May; 60(4):457-66. PMID: 25838121
28. Desalermos A, Tan X, Muthiah R, Arvanitis M, Wang Y, Li D, Kourkoumpetis TK, **Fuchs BB**, **Mylonakis E**. A Multi-host approach for the systematic analysis of virulence factors in *Cryptococcus neoformans*. *J Infect Dis*. 2015;211(2):298-305. PMID: 25114160
29. Souza AC, **Fuchs BB**, Pinhati HM, Siqueira RA, Hagen F, Meis JF, Mylonakis E, Colombo AL. Candida parapsilosis resistance to fluconazole: molecular mechanisms and in vivo impact in infected Galleria mellonella larvae. *Antimicrobial Agents and Chemotherapy*. 2015; 59(10):6581-7.
30. Jayamani E, Rajamuthiah R, Larkins-Ford J, **Fuchs BB**, Conery AL, Vilcinskis A, Ausubel F, **Mylonakis E**. Insect-derived cecropins display activity against *Acinetobacter baumannii* in whole animal high throughput *Caenorhabditis elegans* model. *Antimicrobial Agents and Chemotherapy*. 2015; 59(3):1728-37.

31. Rossoni RD, Barbosa JO, Vilela SF, dos Santos JD, de Barros PP, Prata MC, Anbinder AL, **Fuchs BB**, Jorge AO, **Mylonakis E**, Junquiera JC. Competitive interactions between *C. albicans*, *C. glabrata*, and *C. krusei* during biofilm formation and development of experimental candidiasis. *PLoS ONE*. 2015; 10(7):e0131700.
32. Rajamuthiah R, Jayamani E, Conery AL, **Fuchs BB**, Kim W, Johnson T, Vilcinskas A, Ausubel F, **Mylonakis E**. A defensin from the model beetle *Tribolium castaneum* acts synergistically with telavancin and daptomycin against multidrug resistant *Staphylococcus aureus*. *PLoS ONE*. 2015; 10(6):e0128576.
33. Kim W, Conery AL, Rajamuthiah R, **Fuchs BB**, Ausubel F, **Mylonakis E**. Identification of an antimicrobial agent effective against methicillin-resistant *Staphylococcus aureus* persists using a fluorescent based screening strategy. *PLoS ONE*. 2015; 10(6):e0127640.
34. Rajamuthiah R, **Fuchs BB**, Conery AL, Kim W, Jayamani E, Kwon B, Ausubel F, **Mylonakis E**. Repurposing salicylanilide anthelmintic drugs to combat resistant *Staphylococcus aureus*. *PLoS ONE*. 2015;10(4):e0124595.
35. Rajamuthiah R, Jayamani E, Majed H, Conery AL, Kim W, Kwon B, **Fuchs BB**, Kelso MJ, Ausubel FM, **Mylonakis E**. Antibacterial properties of 3-(Phenylsulfonyl)-2-pyrazinecarbonitrile. *Bioorg Med Chem Lett*. 2015;25(22):5203-7. PMID: 26459212
36. **Kantor R**, A DeLong, M Balamane, L Schreier, RM Lloyd, W Injera, L Kamle, F Mambo, S Muyonga, D Katzenstein, J Hogan, N Buziba, L Diero. HIV Diversity and drug resistance from plasma and non-plasma analytes in a large treatment program in Western Kenya Genotyping. *Journal of the International AIDS Society* 2014;17:19262. PMC4238965.
37. S Sirivichayakul, **Kantor R**, AK DeLong, R Wongkunya, S Mekprasan, K Ruxrungtham, AH Sohn, P Phanuphak. Transmitted HIV drug resistance at the Thai Red Cross Anonymous Clinic in Bangkok: Results from three consecutive years of annual surveillance. *Journal of Antimicrobial Chemotherapy* 2014; 70:1146-9. PMID: 25525199. PMCID: PMC4375389.
38. **Kantor R**, L Smeaton, S Vardhanabhuti, SE Hudelson, CL Wallis, S Tripathi, MG Morgado, S Saravanan, P Balakrishnan, M Reitsma, K Braun, S Hart, J Mellors, E Halvas, J Hakim, **Flanigan T**, N Kumarasamy, TB Campbell, SH Eshleman, on behalf of the A5175 Study Team. Baseline HIV Drug Resistance is Independently Associated with Virologic Failure: Results from the Multi-national PEARLS (ACTG A5175) Clinical Trial. *Clinical Infectious Diseases* 2015;60:1541-9. PMCID 4425827.
39. KK Tee, **Kantor R**, S Sungkanuparph, Y Takebe, PL MBBS, R Ditangco, P Phanuphak, T Sirisanthana, B Sim, W Ratanasuwon, P Kantipong, A Kamarulzaman, on behalf of the TREAT Asia Studies to Evaluate Resistance – Monitoring (TASER-M) Database. Transmission networks of HIV-1 among men who have sex with men in east and southeast Asia. *Journal of AIDS*. 2015;70:e28-30. PMCID 4556551.

40. Zhang L, J Wang, M Coetzer, S Angione, A Tripathi, **Kantor R**. One step Ligation on RNA Amplification (LRA) for the Detection of Point Mutations. *J Mol Diagn*. 2015;17(6):679-88. PMID: 26322949
41. RA Oyomopito, YJ Chen, S Sungkanuparph, **Kantor R**, T Merati, WC Yam, T Sirisanthana, PCK Li, P Kantipong, P Phanuphak, CKC Lee, A Kamarulzaman, R Ditangco, SW Huang, AH Sohn, M Law, YMA Chen, on behalf of the TREAT Asia Studies to Evaluate Resistance (TASER). Risk group characteristics and viral transmission clusters in South-East Asian patients infected with HIV-1 circulating recombinant form (CRF)01_AE and subtype B. *Kaohsiung J Med Sci*. 2015;31(9):445-53. PMID: 26362956
42. Wilson EM, Singh A, Hullsiek KH, Gibson D, Henry WK, Lichtenstein K, Onen NF, **Kojic E**, Patel P, Brooks JT, Seriti I, Baker JV, CDC SUN study investigators. Monocyte activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. *J Infect Dis* 2014; 210(9):1396-406, PMID: 24813472.
43. Dugdale C, Chow B, Yakirevich E, **Kojic E**, Knoll B. Prolonged pyrexia and hepatitis: Q fever. *Am J Med* 2014; 127(10):928-30, PMID: 24929020.
44. Morrow KM, Rohan L, Rosen RK, Fava J, Ham, A, Friend D, Katz D, **Kojic EM**, Buckheit R. Vaginal film user evaluations: Developer considerations from initial impressions and user sensory perceptions and experiences during vaginal sex. *AIDS Res Human Retroviruses* 2014; 30(S1):A145-6.
45. Morrow KM, Rosen RK, Vargas S, Katz D, Fava J, **Kojic EM**, Friend D, Rohan L, Ham A, Buckheit R. More...? Less...? Just right...? The role of perceived volume in gel and film perceptibility during intercourse, and its impact on product preference. *AIDS Res Human Retroviruses* 2014; 30(A1):A145.
46. Escota G, Patel P, Brooks J, Bush T, Conley L, Baker J, **Kojic E**, Hammer J, Onen N. The veterans aging cohort study index is an effective tool to assess baseline frailty status in a contemporary cohort of HIV-infected persons. *AIDS Res Hum Retroviruses* 2015; 31(3):313-7, PMID: 25495766.
47. Cioe PA, Baker J, **Kojic EM**, Onen N, Hammer J, Patel P, Kahler CW; SUN study investigators. Elevated soluble CD14 and lower D-dimer are associated with cigarette smoking and heavy episodic alcohol use in persons living with HIV (PLWH). *JAIDS* 2015;70(4):400-5. PMID: 26181818.
48. **Kwara A**, Enimil A, **Gillani FS**, Yang H, Sarfo A, Dompok A, Ortsin A, Osei-Tutu L, Kwarteng Owusu S, Wiesner L, Norman J, Kurpewski J, Peloquin CA, Ansong D, Antwi S. Pharmacokinetics of first-line antituberculosis drugs using WHO revised dosage in children with tuberculosis with and without HIV coinfection. *J Pediatric Infect Dis* 2015; May 26. pii: piv035. (Epub ahead of print) PMID: 26407268.

49. Frey SE, Peiperl L, McElrath MJ, Goepfert PA, Keefer MC, Baden LR, **Lally MA**, et al. Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1 Uninfected Adult Participants. *Clinical and Vaccine Immunology* 21(11):1589-1599, 2014. PMID25253665. PMC4248765
50. Savel C, Mierzwa S, Gorbach P, **Lally M**, et al, Adolescent Trials Network for HIV/AIDS Interventions. Web-based, mobile-device friendly, self-report survey system incorporating avatars and gaming console techniques. *Journal of Public Health Informatics* 6(2):e191, 2014. PMC4235324
51. Alexander AB, Ott MA, **Lally MA**, et al, Adolescent Trials Network for HIV/AIDS Interventions. Adolescent decision making about participation in a hypothetical HIV vaccine trial. *Vaccine* 33(11):1331-7, 2015. PMID25645175. PMC4379417
52. Mullins TL, **Lally M**, Zimet G, Kahn JA. Clinician Attitudes Toward CDC Interim Pre-Exposure Prophylaxis (PrEP) Guidance and Operationalizing PrEP for Adolescents. *AIDS Patient Care STDS* 29(4):193-203. PMID25692683. PMC4378662
53. Londin E, Loher P, Telonis AG, Quann K, **Lally M**, et al. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. *Proceedings of the National Academy of Sciences* 29(4):193-203, 2015. PMID25713380. PMC4364231
54. Zaller N, Topletz A, Frater S, Yates G, **Lally M**. Profiles of Medicinal Cannabis Patients Attending Compassion Centers in Rhode Island. *J Psychoactive Drugs* 47(1):18-23, 2015. PMID25715068
55. Kurth AE, **Lally MA**, Choko AT, Inwani IW, Fortenberry JD. HIV testing and linkage to services for youth. *Journal of the International AIDS Society* 18(2 Suppl 1):19433, 2015. PMID25724506. PMC4344538
56. **Li M**. Proteomics in the investigation of HIV-1 interactions with host proteins. *Proteomics Clin Appl*. 2015 Feb;9(1-2):221-34.
57. Arvanitis M, Zacharioudakis IM, Zervou FN, Ziakas PD, **Mermel LA**, **Mylonakis E**. Antimicrobial lock solutions as a method to prevent central line-associated bloodstream Infections: A meta-analysis of randomized controlled trials. *Clin Infect Dis* 59:1741-1749, 2014.
58. Fisman D, Patrozou E, Carmeli Y, Perencevich E, Tuite AR, **Mermel LA**, and the Geographical Variability of Bacteremia Study Group. Geographical variability in the likelihood of bloodstream infections due to gram-negative bacteria: correlation with proximity to the equator and health care expenditure. *PLOS ONE*. 9(12):e114548, 2014.
59. **Mermel LA**. Diverse sources of *C. difficile* infection (letter). *N Engl J Med* 370:182-183, 2014.

60. Jiang Y, Baier R, Morphis B, **Mermel LA**, Viner-Brown S. Rhode Island Clostridium difficile infection trends and laboratory ID events ranking. *Med Health RI* 97:60-63, 2014.
61. Cohen DM, Levinson A, Mazer J, Lueckel S, Carino G, **Mermel LA**. Insertion and use of arterial catheters: A survey of clinician anti-septic technique. *Med Health RI* 97:24-27, 2014.
62. Dai J, Leone A, **Mermel LA**, Hwanga K, Pareeka G, Schiff S, Golijanin D, Renzulli J. Rectal swab culture-directed antimicrobial prophylaxis for prostate biopsy and risk of post-procedure infection: a cohort study. *Urology* 85:8-14, 2015.
63. Luther MK, Bilida S, **Mermel LA**, LaPlante KL. Ethanol and isopropyl alcohol exposure increases biofilm formation in Staphylococcus aureus and Staphylococcus epidermidis. *Infect Dis Ther.* 4:219-226, 2015.
64. Alexandrou E, Ray-Barruel G, Carr P, Frost S, Inwood S, Higgins N, Lin F, Alberto L, **Mermel LA**, Rickard CM. Brief report: International prevalence of the use of peripheral intravenous catheters. *J Hosp Med.* 10:530-533, 2015.
65. Parienti J-J, Mongardon N, Mégarbane B, Mira J-P, Kalfon P, Gros A, Marqué S, Thuong M, Pottier V, Ramakers M, Savary B, Seguin A, Valette X, Terzi N, Sauneuf B, Cattoir V, **Mermel LA**, du Cheyron D, for the 3SITES study Group. Intravascular complications of central venous catheterization by insertion site. *N Engl J Med.* 373:1220-1229, 2015.
66. Cohen DM, Carino GP, Heffernan DS, Lueckel SN, Mazer J, Skierkowski D, Machan JT, **Mermel LA**, Levinson AT. Arterial catheter use in the ICU: A national survey of antiseptic technique and perceived infectious risk. *Crit Care Med.* 2015;43(11):2346-53.
67. **Mermel LA**. The human-microbe metaorganism, evolution, and extraterrestrial colonization. *Future Microbiol.* 10:1269-70, 2015.
68. Classen DC, **Mermel LA**. Specialty society clinical practice guidelines—Time for evolution or revolution? *JAMA.* 314:871-2, 2015.
69. **Mermel LA**. Infection control and prevention programs in integrated healthcare delivery systems in the time of ebola and enterovirus d68. The challenge before us (letter). *Infect Control Hosp Epidemiol* 36:239, 2015.
70. **Mermel LA**. Catheter tip cultures: Are they really relegated to the archives of historical medical interest (letter)? *Clin Infect Dis.* 60:975, 2015.
71. **Mermel LA**, Parienti JJ. Does my patient still need this central venous catheter (letter). *JAMA Intern Med.* 175:861-862, 2015.
72. **Mermel LA**. Effectiveness of Minocycline/Rifampin vs Chlorhexidine/Silver Sulfadiazine-Impregnated Central Venous Catheters (letter). *J Am Coll Surg.* 221:891-892, 2015.

73. **Mermel LA.** Influenza, fever, restrictions for healthcare workers and pandemic planning: Time for reappraisal (letter). *Infect Control Hosp Epidemiol.* 2015;36(10):1248. PMID: 26190801
74. Jayamani E, **Mylonakis E.** Effector triggered manipulation of host immune response elicited by different pathotypes of *Escherichia coli*. *Virulence.* 2014;5(7):733-9. PMID: 25513774
75. Zervou FN, Zacharioudakis IM, **Mylonakis E.** 6 weeks of antibiotics was non-inferior to 12 weeks for clinical cure in pyogenic vertebral osteomyelitis. *Ann Intern Med.* 2015 May 19;162(10):JC7. doi: 10.7326/ACPJC-2015-162-10-007. PMID: 25984880
76. Ziakas PD, Zacharioudakis IM, Zervou F, **Mylonakis E.** MRSA prevention strategies in the intensive care unit: A clinical decision analysis. *Crit Care Med.* 2015;43(2):382-93. PMID: 25377019
77. Hu Y, Huang X, Lu S, Hamblin MR, **Mylonakis E,** Zhang J, Xi L. Photodynamic therapy combined with terbinafine against chromoblastomycosis and the effect of PDT on *Fonsecaea monophora* in vitro. *Mycopathologia.* 2015;179;(1-2):103-9. PMID: 25366276
78. Grigoras CA, Ziakas PD, Jayamani E, **Mylonakis E.** ATG16L1 and IL23R Variants and genetic susceptibility to Crohn's disease: Mode of inheritance based on meta-analysis of genetic association studies. *Inflamm Bowel Dis.* 2015;21(4):768-76. PMID: 25738374
79. Cameron DR, Mortin LI, Rubio A, **Mylonakis E,** Moellering RC, Eliopoulos GM, Peleg AY. Impact of daptomycin resistance on *Staphylococcus aureus* virulence. *Virulence.* 2015;6(2):127-31. PMID: 25830650
80. Paudel S, Zacharioudakis IM, Zervou F, Ziakas PD, **Mylonakis E.** Prevalence of *C. difficile* infection among solid organ transplant recipients: A meta-analysis of published studies. *PLoS ONE.* 2015;10(4):e0124483. PMID: 25886133
81. **Mylonakis E,** Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: A clinical trial. *Clin Infect Dis.* 2015;60(6):892-9. PMID: 25586686
82. Ziakas PD, Zacharioudakis IM, Zervou F, Grigoras CA, Pliakos EE, **Mylonakis E.** Asymptomatic carriers of toxigenic *C. difficile* in long-term care facilities: A meta-analysis of prevalence and risk factors. *PLoS ONE.* 2015;10(2):e0117195
83. Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, **Mylonakis E.** Colonization with toxinogenic *C. difficile* upon hospital admission and risk of infection: A systematic review and meta-analysis. *Am J Gastroenterol.* 2015;110(3):381-90. PMID: 25732416

84. Siettos CI, Anastassopoulou C, Russo L, Grigoras C, **Mylonakis E**. Modeling the 2014 Ebola virus epidemic – Agent-based simulations, temporal analysis and future predictions for Liberia and Sierra Leone. *PLoS Curr.* Mar 9;7. pii: ecurrents.outbreaks.8d5984114855fc425e699e1a18cdc6c9.
85. **Mylonakis E**, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG. Reply to Bauer and Goff. [letter] *Clin Infect Dis.* 2015;61(3):487-8. PMID: 25944341
86. Karanika S, Zacharioudakis IM, Zervou F, **Mylonakis E**. Risk Factors for meticillin-resistant *Staphylococcus aureus* colonization in dialysis patients: a meta-analysis. *J Hosp Infec.* 2015;91(3):257-63. PMID: 26428959
87. Govindan JA, Jayamani E, Zhang X, **Mylonakis E**, Ruvkun G. A dialogue between *E. coli* free radical pathways and the mitochondria of *C. elegans*. *PNAS.* 2015;112(40):12456-61. PMID: 26392561
88. Govindan JA, Jayamani E, Zhang X, Breen P, Larkins-Ford J, **Mylonakis E**, Ruvkun G. Lipid signalling couples translational surveillance to systemic detoxification in *Caenorhabditis elegans*. *Nature Cell Biol* 2015;17(10):1294-303. PMID: 26322678
89. Arvanitis M. **Mylonakis E**. Diagnosis of invasive aspergillosis: recent developments and ongoing challenges. *Eur J Clin Inves.* 2015;45(6):646-52. PMID: 25851301
90. Arvanitis M, **Mylonakis E**. Characteristics, clinical relevance and the role of echinocandins in fungal-bacterial interactions. *Clin Infect Dis.* 2015;1:61 Suppl 6:S630-4. PMID: 26567281
91. Kostoulas X, Murray G, Cerqueira G, Kong J, Bantun F, **Mylonakis E**, Khoo C, Peleg A. The impact of a cross-kingdom signalling molecule of *Candida albicans* on *Acinetobacter baumannii* physiology. *Antimicrob Agents Chemother.* 2015;60(1):161-7. PMID: 26482299
92. **Opal SM**, van der Poll T. Endothelial barrier dysfunction in septic shock. *Journal of Internal Medicine* 2015;277(3):277-293 doi:10.1111./joim.12331.
93. Ramachandran G, Kaempfer R, Chung CS, Shivran A, Chahin AB, Palardy JE, Parejo N, Chen Y, Whitford M, Arad G, Hillman D, Shemesh R, Blackwelder W, Ayala A, Cross AS, **Opal SM**. CD 28 homodimer interface mimetic peptide as a novel inhibitor in experimental models of gram-negative sepsis. *Journal of Infectious Diseases* 2015; 211(6): 995-1003. PMID 25305323
94. Cohen J, Vincent J-L, Adhikari FR, Machado F, Angus D, Calandra T, Jaton K, Giulieri S, Delaloye J, **Opal SM**, Tracey K, van der Poll T, Pelfrene E. Sepsis: a roadmap for future research. *Lancet Infectious Diseases* 2015; (May) 15:581-614

95. Chahin AB, **Opal SM**, Zorzopulos J, Jobes DV, Migdady Y, Yamamoto M, Parejo N, Palardy JE, Horn DL. The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal *Pseudomonas aeruginosa* sepsis. *Antimicrob Agents Chemother* 2015; 59(2): 1225-1229
96. Welte, T, Dellinger P, Ebert H, Ferrer M, **Opal SM**, Schliephake DE Wartenberg-Demand A, Werdan K, Loffler K, Torres A. Design of clinical trials of adjuvant therapies for ventilator-associated pneumonia; The CIGMA study. *Respiratory Medicine* 2015; doi.org/10.1016/j.rmed.2015.03.008.
97. Kalil A, **Opal SM**. Sepsis in the severely immunocompromised host. *Current Infectious Disease Reports* 2015; 17(6): doi:10.1007/511908-015-0487-4.
98. Christaki E, Diza E, Evangelos J, Giamarellos-Bourboulis E, Papadopoulou E, Pistiki A, Droggiti D-I, Georgitis M, Machova A, Lambrelli D, Malisiovas N, Nikolaidis P, **Opal SM**. NK and NKT cell depletion alters the outcome of experimental pneumococcal pneumonia: Relationship with regulation of interferon- γ production. *Journal of Experimental Immunology* 2015; doi:10.1155/2015/532717
99. Marini J, Annane D, Angus D, Brochard L, Ceki LA, Chevert S, Finfer S, Gattinoni L, Iwashyna T, Khan JM, Marshall J, Mira JP, **Opal SM**, Payen D, Pelosi P, Pesenti A, Radermacher P, Ranieri M, Reinhart K, Rubenfeld G, Thompson T, Van den Burgh G, Vincent J-L. Critical care evidence-new directions. *Journal of the American Medical Association* 2015; 313(9):893-894.
100. Fedson DS, Jacobson JR, Rordam OM, **Opal SM**. Treating the host response to Ebola Virus Disease with generic statins and angiotensin receptor blockers. *mBio* 2015; 6(3):e00716-15
101. Laws MB, Danielewicz M, **Rana A**, Kogelman L, Wilson IB. Health Literacy in HIV Treatment: Accurate understanding of Key Biological Treatment Principles is not required for Good ART Adherence. *AIDS Behav.* 2015;19(4):635-44. PMID: 25354736
102. **Rana AI**, Liu T, **Gillani F**, et al. Multiple Gaps in Care Common among Newly Diagnosed HIV Patients. *AIDS Care.* 2015;27(6):679-87. PMID: 25634492
103. Firnhaber C, Smeaton LM, Grinsztejn B, Lalloo U, Faesen S, Samaneka W, Infante R, **Rana A**, Kumarasamy N, Hakim J, Campbell TB. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. *HIV Clin Trials.* 2015 May-Jun; 16(3):89-99. PMID 25979186
104. **Reece RM**, **Cunha CB**, **Rich JD**. *Corynebacterium minutissimum* vascular graft infection: case report and review of 281 cases of prosthetic device-related *Corynebacterium* infection. (2014) *Scand J Infect Dis.* Sep; 46(9):609-16. PMID: 24934988

105. **Reece R**, Norman B, **Kwara A**, **Flanigan T**, **Rana A**. Retention to Care of HIV-positive postpartum females in Kumasi, Ghana. (2015) *J Int Assoc Provid AIDS Care*. Aug 28. Pii:2325957415603507 (Epub ahead of print). PMID: 2631943
106. Kumar N, **Reece R**, Norman B, **Kwara A**, **Flanigan T**, **Rana AI**. Delayed entry to care by men with HIV infection in Kumasi, Ghana. (2015) *Pan African Med Journal* 22, 107, 07/10/2015
107. McNamara BC, Losikoff PT, Huguenin L, Macalino GE, **Rich JD**, Gregory SH. Increasing hepatitis C prevalence and associated risk behaviors among incarcerated young adults. *J Urban Health* 91(2):376-82, 2014. PMID: 23722268
108. Zacharioudakis IM, Zervou FN, Ziakas PD, **Rice LB**, **Mylonakis E**. VRE Colonization among dialysis patients: A meta-analysis of prevalence, risk Factors and significance. *Am J Kidney Dis*. 2015;65(1):88-97. PMID: 25042816
109. Arias CA, **Rice LB**. A New AAC Section: Translating Resistance to the Bedside. *Antimicrob Agents Chemother*. 2015 Aug;59(8):4365. doi: 10.1128/AAC.01138-15. No abstract available. PMID:26185272
110. Sacco E, Cortes M, Josseaume N, Bouchier C, Dubée V, Hugonnet JE, Mainardi JL, **Rice LB**, Arthur M. Mutation landscape of acquired cross-resistance to glycopeptide and β -lactam antibiotics in *Enterococcus faecium*. *Antimicrob Agents Chemother*. 2015 Sep;59(9):5306-15. doi: 10.1128/AAC.00634-15. Epub 2015 Jun 15. PMID: 26077262
111. **Rice LB**. Will use of combination cephalosporin/azithromycin therapy forestall resistance to cephalosporins in *Neisseria gonorrhoeae*?. *Sex Transm Infect*. 2015 Jun;91(4):238-40. doi: 10.1136/sextrans-2014-051730. Epub 2015 Apr 29. No abstract available. PMID: 25926405
112. Green TC, Ray M, Bowman SE, McKenzie M, **Rich JD**. Two cases of intranasal naloxone self-administration in opioid overdose. *Subst Abuse* 35(2):129-32, 2014. PMID: PMC4019939
113. **Rich JD**, Chandler R, Williams BA, Dumont D, Wang EA, Taxman FS, Allen SA, Clarke JG, Greifinger RB, Wildeman C, Osher FC, Rosenberg S, Haney C, Mauser M, Western B. How health care reform can transform the health of criminal justice-involved individuals. *Health Aff* 33(3):462-67, 2014. PMID: PMC4034754
114. Patel K, Boutwell A, Brockmann B, **Rich JD**. Integrating correctional and community health care for formerly incarcerated persons eligible for Medicaid. *Health Aff* 33(3):468-73, 2014. PMID: PMC4028698
115. Rosen DL, Dumont D, Cislo AM, Brockmann BW, Traver A, **Rich JD**. Medicaid policies and practices in US State prison systems. *Am J Public Health* 104(3):418-20, 2014. PMID: PMC3953759

116. Westergard RP, **Rich JD**. HIV and re-incarceration: time for a comprehensive approach. *Lancet HIV* S2352-3018 (14):70025-7, 2014. (comment) PMID: PMC4259282
117. Brockmann BW, Rosen DL, Dumont DM, Cislo AM, **Rich, JD**. Brockmann et al. Respond. (letter) *Am J Pub Health* 104(8):e4-5, 2014. PMID: 24922139
118. Green TC, Bratberg J, Dauria EF, **Rich JD**. Responding to opioid overdose in Rhode Island: where the medical community has gone and where we need to go. *RI Med J* 29-33, October, 2014.
119. Zervou, FN, Zacharioudakis IM, Ziakas PD, **Rich JD, Mylonakis E**. Prevalence of and risk factors for methicillin-resistant staphylococcus aureus colonization in HIV Infection: a meta-analysis. *Clin Infect Dis* 59(9):1302-11, 2014. PMID: PMC3348950
120. **Rich JD**, Allen SA, Williams BA. The need for higher standards in correctional healthcare to improve public health. *J Gen Int Med* 30(4):503-7, 2014. PMID: PMC4371015
121. **Rich JD**, McKenzie M, Larney S, Wong JB, Tran L, Clarke J, Noska A, Reddy M, Zaller N. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomized, open-label trial. *Lancet* 386(9991):350-9, 2015. PMID: PMC4522212
122. **Noska A**, Mohan A, Wakeman S, **Rich JD**, Boutwell A. Managing opioid use disorder during and after acute hospitalization. *J Addict Behav, Ther Rehab* 4(2):1-11, 2015. PMID: PMC4527170
123. Hammett TM, Donahue S, LeRoy L, Montague B, Rosen D, Solomon L, Costa M, Wohl D, **Rich JD**. Transitions to care in the community for prison releases with HIV: a qualitative study of facilitators and challenges in two states. *J Urban Health* 92(4):650-6, 2015. PMID: PMC4524841
124. Christopher PP, Stein MD, Springer SA, **Rich JD**, Johnson JE, Lidz CW. An exploratory study of therapeutic misconception among incarcerated clinical trial participants. *AJOB Empirical Bioethics* Posted Online June 24, 2015, doi 10.1080/23294515.2015.1058303.
125. **Rich JD**, Adashi EY. Ideological anachronism involving needle and syringe exchange programs. Lessons from the Indiana HIV outbreak. *JAMA* 314(1): 23-4, 2015. PMID: PMC4496270
126. Wakeman SE, **Rich JD**. Substance use disorders and avoidable mortality after prison. *Lancet Psychiatry* 5(2):369-70, 2015. (comment) PMID: PMC4461078
127. Gongvatana A, Correia S, Dunsiger S, Gauthier L, Devlin KN, Ross S, Navia B, **Tashima KT**, DeLaMonte S, Cohen RA. Plasma cytokine levels are related to brain volumes in HIV-infected individuals. (2014) *J Neuroimmune Pharmacol*. Dec; 9(5):740-50. PMID: 25273619

128. Clark US, Walker KA, Cohen RA, Devlin KN, Folkers AM, Pina MJ, **Tashima KT**. Facial emotion recognition impairments are associated with brain volume abnormalities in individuals with HIV. (2015) *Neuropsychologia*. Apr; 70:263-71. PMID: 25744868
129. Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczek D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister /S: GS-US-292-004/0111 Study Team. (**Tashima KT** as one of 181 Collaborators.) Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection; two randomized, double-blind, phase 3, non-inferiority trials. (2015) *Lancet*. June 27; 385(9987):2606-15. PMID: 25890673
130. Ofotokun I, Na LH, Landovitz RJ, Ribaldo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS: AIDS Clinical Trials Group (ACTG) A5257 team. (**Tashima KT** as one of 87 Collaborators.) (2015) *Clin Infect Dis*. Jun 15; 60(12):1842-51 PMID: 25767256
131. Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Stanton CA, Papandonatos GD, Shuter J, Bicki A, Lloyd-Richardson EE, deDios MA, Morrow KM, Makgoeng SB, **Tashima KT**, Niaura RS. Outcomes of a Tailored Intervention for cigarette smoking cessation among Latinos living with HIV/AIDS. (2015) *Nicotine Tob Res*. Aug; 17(8):975-82. PMID: 26180222 PMCID: PMC4580545
132. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Brau N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M: ION-4 Investigators. (**Tashima KT** as one of 60 Collaborators.) Ledipasvir and Sofosbuvir for HCV in patients coinfecting with HIV-1. (2015) *N Engl J Med*. Aug 20; 373(8):705-13. PMID: 26196665
133. **Tashima KT**, Mollan KR, Na L, Gandhi RT, Klingman KL, Fichtenbaum CJ, Andrade A, Johnson VA, Eron JJ, Smeaton L, Haubrich RH. Regimen selection in the OPTIONS Trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity. (2015) *HIV Clin Trials*. 16(4):147-56. PMID: 26212575
134. Young B, Squires KE, **Tashima K**, Henry K, Schneider S, LaMarca A, Zhoa HH, Ross LL, Shaefer MS. Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine. (2015) *HIV Clin Trials*. Aug; 16(4):125-9. PMID: 26133089
135. Freiman JM, Huang W, White LF, Geng EH, Hurt CB, **Taylor LE**, Overton ET, Cachay ER, Kitahata MM, Moore RD, Rodriguez B, Mayer KH, Linas BP. Current practices of screening for incident hepatitis C Virus (HCV) infection among HIV-infected, HCV-Uninfected individuals in primary care. *Clin Infect Dis*. 2014 Dec 15;59(12):1686-93.

136. Sangal RB, **Taylor LE**, Gillani F, Poppas A, Klinger JR, Ventetuolo CE. Risk of echocardiographic pulmonary hypertension in individuals with human immunodeficiency virus-hepatitis C virus coinfection. *Ann Am Thorac Soc*. 2014 Dec;11(10):1553-9.
137. Blackard JT, Ma G, Welge JA, King C, **Taylor LE**, Mayer KH, Klein RS, Celentano DD, Sobel J, Jamieson DJ, Gardner L. GB Virus C (GBV-C) Infection in Hepatitis C Virus (HCV) Seropositive Women with or at Risk for HIV infection. *PLoS ONE*. 2014 Dec. 10;9(12):e114467.
138. Kofman A, Litwin AH, Swan T, Pinkston M, Rizzo B, Bryant V, **Taylor LE**. Short Communication: Heterogeneity in Drug and Alcohol Use-Related Exclusion Criteria in Direct Acting Antiviral Agent Hepatitis C Treatment Trials for Individuals Coinfected with Hepatitis C Virus and HIV. *Clin Res HIV/AIDS* 2015 2(2):1019.
139. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, **Taylor LE**. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. *Ann Intern Med*. 2015 Aug 4;163(3):215-23.
140. Grebely J, Dore GJ, Greenwald R, Swan T, Barua S, **Taylor LE**. Time to really separate fact from fiction: Hepatitis C treatment and people who use drugs. *Annals of Internal Medicine* 2015 (Accepted September 24th, 2015, Manuscript Number, L15-0485) (Letter, IF 16.10)
141. **Touzard Romo F**, Livak B, Aziz M, Huesgen E, Colton B, Blake M, Kessler H. Recovery of renal function and virologic suppression following tenofovir discontinuation. *J AIDS Clin Res* 2014, 5 (11): 1-5.
142. **Touzard Romo F**, Gillani FS, Ackerman P, Rana A, Kojic EM, Beckwith CG. Monitored viral load: a measure of HIV treatment outcomes in an outpatient setting in Rhode Island. *RI Med J* 2015; 98(1): 26-30. PMID: 667637
143. **Touzard Romo F**, Resnick B, Perez-Cioe M, Flanigan TP, Kojic E, Beckwith CG. Outpatient Parenteral Antibiotic Therapy in an Academic Practice in Rhode Island. *RI Med J* 2015;98 (1):38-42. PMID: 667656
144. **Touzard Romo F**, Smeaton LM, Campbell TB, Riviere C, Mngqibisa R, Nyirenda M, Supparatpinyo K, Kumarasamy N, Hakim JG, **Flanigan TP**. Renal and Metabolic Toxicities Following Initiation of HIV-1 Treatment Regimen in a Diverse, Multinational Setting: a Focused Safety Analysis of ACTG PEARLS (A5175). *HIV Clinical Trials* 2014; 15 (6): 246-260. PMID: 667617
145. **Noska A**, **Tunkel AR**. Central nervous system infections in the elderly. *Curr Geriatrics Rep* 2015;4:96-104.
146. George P, **Tunkel AR**, Dollase R, Gruppuso P, Dumenco L, Rapoza B, Borkan J. The Primary Care-Population Medicine Program at the Warren Alpert Medical School of Brown University. *Rhode Island Med J* 2015;98(9):16-21.

147. Lantini R, **van den Berg JJ**, Roberts MB, Bock BC, Stein LAR, Parker DR, Friedmann PD, Clarke JG. Characteristics of smoking used cigarettes among an incarcerated population. *Psychol Addict Behav*. 2014; 29, 254-258. doi.org/10.1037/adb0000019. PMID: 25180554
148. **van den Berg JJ**, Larson HE, Zimet GD, **Lally MA**. Bundling human papillomavirus vaccination and rapid human immunodeficiency virus testing for young gay and bisexual men. *LGBT Health*. 2014;1(3):233-237. doi:10.1089/lgbt.2014.0028.
149. Morrow KM, Underhill K, **van den Berg JJ**, Vargas S, Rosen RK, Katz DF. User-identified gel characteristics: A qualitative exploration of perceived product efficacy of topical vaginal microbicides. *Arch Sex Behav*. 2014;43(7):1459-67. doi: 10.1007/s10508-013-0235-5. PMID: 24452632
150. **van den Berg JJ**, Bock BC, Roberts MB, Stein LAR, Friedmann PD, Martin SA, Clarke JG. Cigarette smoking as an expression of independence and freedom among inmates in a tobacco-free prison in the United States. *Nicotine Tob Res*. 2014;16(2):238-42. doi: 10.1093/ntr/ntt163. PMID: PMC3880237.
151. **van den Berg JJ**, Rosen RK, Bregman DE, Thompson LA, Jensen KJ, Kiser PF, Katz DF, Buckheit K, Buckheit RW Jr, Morrow KM. "Set it and forget it": Women's perceptions and opinions of long-acting topical vaginal gels. *AIDS Behav*. 2014;18(5):862-70. doi: 10.1007/s10461-013-0652-4. PMID: PMC4018755.
152. Operario D, Gamarel KE, Grin BM, Lee JH, Kahler CW, Marshall BDL, **van den Berg JJ**, Zaller ND. Sexual minority health disparities in adult men and women in the United States: National Health and Nutrition Examination Survey 2001-2010. *Am J Public Health*. 2015 Aug 13:e1-e8.
153. Rosen RK, **van den Berg JJ**, Vargas SE, Senocak N, Shaw JG, Buckheit Jr RW, Smith KA, Guthrie KM. Meaning-making matters in product design: Users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings. *Contraception*. 2015 Aug 11. pii: S0010-7824(15)00542-9. doi: 10.1016/j.contraception.2015.08.007. [Epub ahead of print]. PMID: 26276246
154. Clarke JG, Martin SA, Martin RA, Stein LAR, **van den Berg JJ**, Parker DR, McGovern AR, Roberts MB, Bock BC. Changes in smoking-related symptoms during enforced abstinence of incarceration. *J Health Care Poor Underserved*. 2015;26(1):106-18. doi:10.1353/hpu.2015.0014. PMID: 25702731
155. Marshall BDL, Shoveller JA, Kahler CW, Koblin BA, Mayer KH, Mimiaga MJ, **van den Berg JJ**, Zaller ND, Operario D. Heavy drinking trajectories among men who have sex with men: A longitudinal, group-based analysis. *Alcohol Clin Exp Res*. 2015;39(2):380-89. doi:10.1111/acer.12631. PMID:25684055

156. Bernstein MH, McSheffrey SN, **van den Berg JJ**, Vela JE, Stein LAR, Roberts M, Martin RA, Clarke JG. The association between impulsivity and alcohol/drug use among prison inmates. *Addict Behav.* 2015;42:140-143. doi:10.1016/j.addbeh.2014.11.016. PMID: 25462662